Bioiberica Earns Frost & Sullivan 2025 European New Product Innovation Award for Native Type II Collagen Ingredient

Bioiberica has been awarded the 2025 European New Product Innovation Recognition by Frost & Sullivan for its clinically validated native type II collagen ingredient, Collavant n2. The award underscores the company’s emphasis on scientifically validated collagen ingredients, clinical substantiation, and vertically integrated manufacturing within Europe’s joint health and collagen solutions market, a February 18 press release from the company explains.¹

Highlights of the Award

Frost & Sullivan’s New Product Innovation Recognition is awarded annually to companies demonstrating measurable differentiation, customer value creation, and competitive strengthening through strategic product development, the press release explains. Award recipients are evaluated through a benchmarking process that measures strategy effectiveness and execution. In Bioiberica’s case, the company was recognized for aligning long-term scientific investment with evolving market demand for evidence-backed joint health solutions, while maintaining regulatory rigor and operational consistency. “Bioiberica distinguishes Collavant n2 by providing mechanistic clarity and efficacy both in terms of joint comfort and potential cartilage preservation, setting it apart in a market that often lacks transparent clinical substantiation,” stated Sreedevi Kakkad, Senior Research Analyst, TechVision at Frost & Sullivan.

“We’re honored to receive this prestigious award, and we’d like to thank everyone who has contributed to this milestone—from our exceptional scientists and technical experts to our production specialists, regional distributors and more,” states Antonio Vendrell, Marketing & Communications Director at Bioiberica. “To us, collagen is much more than just a molecule. It is a tool that, through in-depth research and refinement, unlocks virtually limitless opportunities for health and wellbeing innovation. Through our continuous efforts to clinically characterize the benefits of Collavant n2, as well as our initiatives to dispel common myths and misconceptions in the collagen market, we hope to empower our industry partners to unlock the next generation of collagen innovation.”

Collavant n2 Collagen Ingredient

At the center of the recognition is Collavant n2, a native type II collagen derived from chicken sternum cartilage. Unlike hydrolyzed collagen peptides that typically require gram-level daily doses, Collavant n2 is standardized at 40 mg per day and retains its undenatured molecular structure. This structural preservation enables an immune-mediated mechanism of action designed to promote joint comfort and support cartilage health. The ingredient is supported by randomized, controlled clinical trials evaluating endpoints such as joint comfort, mobility, and functional performance.

In an interview with Nutritional Outlook at Supplyside Global 2025, Vendrell explained recently published results from a placebo-controlled study on Collavant n2.² “These results are about showing through a biomarker how Collavant n2 is effective positively versus a placebo group,” he stated. “There is a biomarker called CTX-II, and if this biomarker is present, then there is a degradation of the cartilage. In the placebo group, we've got certain amount of this biomarker, and on the group that had Collavant n2, we've got another amount. The difference is close to a 40 percentage point, showing that the healthy subjects that used Collavant had this 40 percentage points benefit of having less CTX-II, meaning that Collavant n2 preserves the cartilage in a higher way than if you don't take it.”

Joint Support in Functional Milk Beverage

Earlier this year, Bioiberica and dairy producer Lactalis Spain announce they had partnered to launch Puleva Vita Calcio Colágeno, a functional milk beverage with Collavant n2.³ The launch aims to provide consumers in the mainstream market easy access to joint health support and is the first native type II collagen-enriched milk drink to be released in Spain.

This article was created with assistance from AI. The content has been reviewed and edited by Erin McEvoy, Associate Editor. For more information on the extent and nature of AI usage, please contact us.

References

1. Biobierica. We received Frost & Sullivan’s 2025 European New Product Innovation Award for Clinically Validated Native Type II Collagen. Published February 18, 2026. Accessed February 26, 2026. https://www.bioiberica.com/en/inspiring-insights/received-frost-sullivans-2025-european-new-product-innovation-award-clinically
2. McEvoy E, Vendrell A. Joint health and healthy aging: interview with Bioiberica. Published November 3, 2025. Accessed February 26, 2026. https://www.nutritionaloutlook.com/view/joint-health-and-healthy-aging-interview-with-bioiberica
3. McEvoy E. Bioiberica and Lactalis Spain introduce native type II collagen milk beverage. Published January 21, 2026. Accessed February 26, 2026. https://www.nutritionaloutlook.com/view/bioiberica-and-lactalis-spain-introduce-native-type-ii-collagen-milk-beverage